Chemistry:IBI311
From HandWiki
IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.[1][2][3]
References
- ↑ "Innovent doses first patient in Phase III study of IBI311 for TED". Clinical Trials Arena. 8 May 2023. https://www.clinicaltrialsarena.com/news/innovent-first-patient-ted/.
- ↑ "IGF Market And Pipeline Insights 2023" (in en). https://www.precisionbusinessinsights.com/market-reports/igf-market.
- ↑ Li, Chen; Hao, Jun; Wang, Chuangshi; Yang, Jie; Zheng, Yitian; Zhang, Kuo; Hui, Wen; Meng, Xiangbin et al. (3 August 2023). "Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022". Drug Design, Development and Therapy 17: 2315–2324. doi:10.2147/DDDT.S409617. ISSN 1177-8881. PMID 37559911.
 |  |
